After posting positive late-stage results for its rare blood disease drug, Sanofi has been handed a priority review from the FDA for sutimlimab.
The French Big Pharma is hoping that its complement C1s inhibitor will get a green light for use in cold agglutinin disease (CAD), a rare condition in which the immune system turns on the patient’s red blood cells.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,